Acme Generics LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Acme Generics LLP Pharmaceutical Export Portfolio Dataset — 4 Products, $738.2K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Acme Generics LLP — Pharmaceutical Exporter Profile (2026) | 4 Products, $738.2K Trade | TransData Nexus

Acme Generics LLP

Indian Pharmaceutical Exporter · Combination Drugs Specialist · $738.2K Total Trade · DGFT Verified

Acme Generics LLP is an Indian pharmaceutical exporter with a total trade value of $738.2K across 4 products in 3 therapeutic categories. Based on 41 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Salicylic ($245.0K), Levothyroxine ($239.1K), Acetylsalicylic ($181.3K).

Acme Generics LLP — Export Portfolio & Destination Treemap

Acme Generics LLP pharmaceutical export portfolio — 4 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Acme Generics LLP? — Company Overview & Market Position

Acme Generics LLP, established on March 13, 2015, in Chandigarh, India, specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company was registered under the Corporate Identification Number (CIN) AAD-5392. In April 2021, Ruby Shah and Viral Shah were appointed as Designated Partners, overseeing the company's strategic direction and operations. Acme Generics operates from its headquarters at Plot No-75, Industrial Area, Phase-1, Chandigarh, India.

In the fiscal year ending March 31, 2021, Acme Generics reported a 13.33% increase in total revenue, reflecting its growing presence in the pharmaceutical export market. The company's net worth remained stable, indicating consistent financial health. Acme Generics is recognized for its expertise in niche segments such as oral hormones, including female sex hormones and levothyroxine, as well as liquid and lyophilized injectables.

What Does Acme Generics LLP Export? — Product Portfolio Analysis

Top Products by Export Value

1Salicylic$245.0K 2

Product Portfolio — Top 4 by Export Value

Acme Generics LLP exports 4 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Salicylic	Combination Drugs	$245.0K	7	1.5%	13
2	Levothyroxine	Diabetes & Endocrine	$239.1K	25	0.3%	15
3	Acetylsalicylic	Combination Drugs	$181.3K	5	4.1%	9
4	Digoxin	Cardiovascular	$72.7K	4	3.3%	4

Acme Generics LLP exports 4 pharmaceutical products across 3 therapeutic categories with a total export value of $738.2K. The top category is Combination Drugs (57.8% of portfolio), followed by Diabetes & Endocrine (32.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Acme Generics LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Acme Generics operates a state-of-the-art manufacturing facility in Northern India, encompassing over 500,000 square feet of space. This facility is equipped to produce 17 billion tablets, 3 billion capsules, 30 million liquid vials/ampoules, and 12 million lyophilized vials annually. The plant specializes in the production of oral solid dosage forms, including tablets and capsules, as well as liquid and lyophilized injectables. Additionally, Acme Generics has expanded its sterile manufacturing capacity to produce an additional 60 million general liquid and lyophilized vials, 60 million liquid and lyophilized vials for oncology, 30 million three-piece ophthalmic containers, and 24 million pre-filled syringes and cartridges annually.

3Key Leadership

The leadership team at Acme Generics includes Designated Partners Ruby Shah and Viral Shah, who have been instrumental in steering the company's strategic initiatives and operational growth. Their leadership has been pivotal in expanding the company's manufacturing capabilities and enhancing its product portfolio. Under their guidance, Acme Generics has achieved significant milestones, including the expansion of its sterile manufacturing capacity and the attainment of various international regulatory approvals.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Acme Generics LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Acme Generics has established a strong presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has been audited and approved by various international regulatory agencies, including the USFDA, UK-MHRA, EU-GMP (Hungary), Health Canada, TGA Australia, ANVISA (Brazil), INVIMA (Colombia), and WHO-Geneva. These approvals underscore Acme Generics' commitment to maintaining high-quality manufacturing standards and its capability to meet the stringent requirements of these markets. The company's adherence to Good Manufacturing Practices (GMP) and other regulatory standards has facilitated its entry and sustained operations in these regions.

2Emerging Markets

Acme Generics has strategically expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are available in countries such as Nigeria, Ghana, Uganda, Kenya, Nepal, Sri Lanka, the Philippines, Vietnam, Cambodia, Laos, Thailand, Yemen, Myanmar, Brazil, Colombia, Guatemala, Nicaragua, Paraguay, Uruguay, Chile, Costa Rica, Venezuela, and Peru. The attainment of WHO prequalification and other international certifications has enabled Acme Generics to access these markets, ensuring that its products meet global quality standards and are accessible to a broader patient population.

Geographic Strategy

Acme Generics LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Acme Generics has achieved significant milestones in the U.S. market, with 38 Abbreviated New Drug Applications (ANDAs) approved and 18 filed and under review. The company has a target of obtaining over 50 ANDA approvals by 2025, reflecting its commitment to expanding its product offerings in the U.S. market. These approvals demonstrate Acme Generics' adherence to the stringent standards set by the U.S. Food and Drug Administration (FDA) and its capability to deliver high-quality generic pharmaceutical products to the U.S. market.

2WHO & EU GMP

Acme Generics has been audited and approved by various international regulatory agencies, including the USFDA, UK-MHRA, EU-GMP (Hungary), Health Canada, TGA Australia, ANVISA (Brazil), INVIMA (Colombia), and WHO-Geneva. These certifications attest to the company's compliance with Good Manufacturing Practices (GMP) and its commitment to maintaining high-quality manufacturing standards. The EU GMP certification, in particular, enables Acme Generics to market its products within the European Union, ensuring that they meet the rigorous quality standards required by European regulators.

3CDSCO & Indian Regulatory

Acme Generics LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Acme Generics operates in a competitive landscape with several key players in the pharmaceutical export market. Competitors include established Indian pharmaceutical exporters such as Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Lupin Pharmaceuticals. While Acme Generics holds a 1.5% market share in the salicylic product category, it faces competition from these larger entities with more extensive product portfolios and market reach. However, Acme Generics' focus on niche segments like oral hormones and its commitment to quality manufacturing standards provide it with a competitive edge in specific therapeutic areas.

2Key Differentiators

Acme Generics' unique strengths include its specialization in niche segments such as oral hormones, including female sex hormones and levothyroxine, as well as liquid and lyophilized injectables. The company's manufacturing facility in Northern India, spanning over 500,000 square feet, enables it to produce a high volume of pharmaceutical products annually. Additionally, Acme Generics' attainment of various international regulatory approvals, including those from the USFDA, UK-MHRA, EU-GMP, and WHO-Geneva, underscores its commitment to maintaining high-quality manufacturing standards and regulatory compliance.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Acme Generics LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Acme Generics has demonstrated a consistent track record in pharmaceutical manufacturing, with a total export value of $738,000 USD across 41 shipments from 2022 to 2026. The company's portfolio includes four products across three therapeutic categories, with a concentration of 100% in its top five products. This focus indicates a strategic approach to product development and market positioning. The company's adherence to international regulatory standards and its expansion into various global markets reflect its reliability and commitment to quality.

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Acme Generics LLP

How many pharmaceutical products does Acme Generics LLP export from India?

Acme Generics LLP exports 4 pharmaceutical products across 3 therapeutic categories. The top exports are Salicylic ($245.0K), Levothyroxine ($239.1K), Acetylsalicylic ($181.3K), Digoxin ($72.7K). Total export value is $738.2K.

What is Acme Generics LLP's total pharmaceutical export value?

Acme Generics LLP's total pharmaceutical export value is $738.2K, based on 41 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Acme Generics LLP cover?

Acme Generics LLP exports across 3 therapeutic categories. The largest are Combination Drugs (57.8%, 2 products), Diabetes & Endocrine (32.4%, 1 products), Cardiovascular (9.8%, 1 products).

Get Full Acme Generics LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.